Amgen 2013 Annual Report Download - page 125
Download and view the complete annual report
Please find page 125 of the 2013 Amgen annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.-
1 -
2
-
3
-
4
-
5
-
6
-
7
-
8
-
9
-
10
-
11
-
12
-
13
-
14
-
15
-
16
-
17
-
18
-
19
-
20
-
21
-
22
-
23
-
24
-
25
-
26
-
27
-
28
-
29
-
30
-
31
-
32
-
33
-
34
-
35
-
36
-
37
-
38
-
39
-
40
-
41
-
42
-
43
-
44
-
45
-
46
-
47
-
48
-
49
-
50
-
51
-
52
-
53
-
54
-
55
-
56
-
57
-
58
-
59
-
60
-
61
-
62
-
63
-
64
-
65
-
66
-
67
-
68
-
69
-
70
-
71
-
72
-
73
-
74
-
75
-
76
-
77
-
78
-
79
-
80
-
81
-
82
-
83
-
84
-
85
-
86
-
87
-
88
-
89
-
90
-
91
-
92
-
93
-
94
-
95
-
96
-
97
-
98
-
99
-
100
-
101
-
102
-
103
-
104
-
105
-
106
-
107
-
108
-
109
-
110
-
111
-
112
-
113
-
114
-
115 -
116 -
117 -
118 -
119 -
120 -
121 -
122 -
123 -
124 -
125 -
126 -
127 -
128 -
129 -
130 -
131 -
132 -
133 -
134 -
135 -
136
-
137
-
138
-
139
-
140
-
141
-
142
-
143
-
144
-
145
-
146
-
147
-
148
-
149
-
150
-
151
-
152
-
153
-
154
-
155
-
156
-
157
-
158
-
159
-
160
-
161
-
162
-
163
-
164
-
165
-
166
-
167
-
168
-
169
-
170
-
171
-
172
-
173
-
174
-
175
-
176
-
177
-
178
-
179
-
180
-
181
-
182
-
183
-
184
-
185
-
186
-
187
-
188
-
189
-
190
-
191
-
192
-
193
-
194
-
195
-
196
-
197
-
198
-
199
-
200
-
201
-
202
-
203
-
204
-
205
-
206
-
207
 |
 |
Long-lived assets:
United States $2,772
$2,906
Puerto Rico 1,822
1,908
ROW 755
512
Total long-lived assets $5,349
$5,326
Major customers
In the United States, we sell primarily to pharmaceutical wholesale distributors. We utilize those wholesale distributors as the principal means of
distributing our products to healthcare providers. In Europe, we sell principally to healthcare providers and/or pharmaceutical wholesale distributors
depending on the distribution practice in each country. We monitor the financial condition of our larger customers, and we limit our credit exposure by setting
credit limits and, for certain customers, may require letters of credit.
We had product sales to three customers each accounting for more than 10% of total revenues for the years ended December 31, 2013, 2012 and 2011.
For 2013, on a combined basis, these customers accounted for 75% and 93% of worldwide gross revenues and U.S. gross product sales, respectively, as
noted in the following table. Certain information with respect to these customers for the years ended December 31, 2013, 2012 and 2011, was as follows
(dollar amounts in millions):
AmerisourceBergen Corporation:
Gross product sales $8,527
$7,556
$7,574
% of total gross revenues 35%
34%
36%
% of U.S. gross product sales 44%
43%
45%
McKesson Corporation:
Gross product sales $6,440
$5,898
$4,591
% of total gross revenues 27%
27%
22%
% of U.S. gross product sales 32%
32%
27%
Cardinal Health, Inc.:
Gross product sales $ 3,209
$ 3,245
$3,021
% of total gross revenues 13%
15%
14%
% of U.S. gross product sales 17%
19%
18%
At December 31, 2013 and 2012, amounts due from these three customers each exceeded 10% of gross trade receivables and accounted for 63% and
61%, respectively, of net trade receivables on a combined basis. At December 31, 2013 and 2012, 35% and 36%, respectively, of trade receivables, net were
due from customers located outside the United States, primarily in Europe. Our total allowance for doubtful accounts as of December 31, 2013 and 2012, was
not material.
F-49